CINGW Cingulate Inc.

BEARISH Impact: 6/10 EFFECT
Horizon weeks Filed Apr 27, 2026 Processed 1mo ago SEC 9999999995-26-001327
IPO/offering going effective
Latest settled — T+20d
CINGW ▼ -68.39% at T+20d
SHORT call ✓ call won +68.39% · α vs SPY +73.34% · entry $0.0601 → $0.0190
Next anchor: T+60d in 6w
Currently $0.0601 · -0.00% from $0.0601 entry (call sign-flipped)
Entry anchored
Apr 27, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.49%
$0.0601
settled 6w ago
T+5d
0.00%
call 0.00% · α +0.40%
$0.0601
settled 5w ago
T+20d
-68.39%
call +68.39% · α +73.34%
$0.0190
settled 15d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Cingulate Inc.'s S-3 shelf registration has become effective, allowing the company and selling stockholders to offer up to 4,208,711 shares of common stock from a prior private placement. The company will not receive proceeds from the resale of these shares, though it may receive funds if warrants are exercised on a cash basis.

Actionable Insight

Monitor for near-term insider or investor selling under this shelf, which could pressure shares. Watch for warrant exercises, which may provide limited cash inflow but further dilute equity. Given Cingulate's history of dilutive financings and prior going concern risks, this shelf adds to overhang without strengthening the balance sheet directly.

Key Facts

  • S-3 shelf registration (File No. 333-295050) became effective on April 24, 2026.
  • Registration covers resale of 4,208,711 shares held by selling stockholders from a January 2026 private placement.
  • Shares include those issued directly, upon conversion of Series A preferred stock, and issuable upon warrant exercise.
  • Cingulate will not receive proceeds from resale, but may receive cash if warrants are exercised non-cashlessly.
  • This is the third S-3 filing in 2026, indicating ongoing reliance on capital markets.

Financial Impact

Potential dilution from up to 4.2 million shares; proceeds from warrant exercises possible but amount undisclosed.

dilutioncash

Risk Factors

  • Equity dilution from resale of 4.2 million shares
  • Downward price pressure from selling stockholders liquidating positions
  • No direct proceeds to company exacerbates cash-constrained operations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001327
Document: 9999999995-26-001327-index.html9999999995-26-001327
Document: 9999999995-26-001327.txt9999999995-26-001327
6 reports for CINGW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CINGW — sortable, filterable
Type Now
Jun 2, 2026
7d ago
8-K
BEARISH ★ 7/10
$0.0601 $0.0601· 0.00%▼ −0.69%$0.0601 (−0.00%)
May 19, 2026
21d ago
8-K
NEUTRAL ★ 2/10
$0.0601 $0.0601· 0.00%▼ −0.19%$0.0601 (+0.00%)
May 14, 2026
26d ago
8-K
NEUTRAL ★ 5/10
$0.0601 $0.0601· 0.00%▲ +1.23%$0.0601 (+0.00%)
May 14, 2026
26d ago
Press Release
NEUTRAL ★ 5/10
$0.0601 $0.0601· 0.00%▲ +1.23%$0.0601 (+0.00%)
Apr 27, 2026
6w ago
EFFECT
BEARISH ★ 6/10
$0.0601 $0.0601· 0.00%▼ −0.49%$0.0601 (−0.00%)
Mar 18, 2026
11w ago
Press Release
MIXED ★ 6/10
$0.0601 $0.0601· 0.00%▲ +0.27%$0.0601 (+0.00%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 9h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access